|
Samalizumab Cohort
|
CLL cells bound by samalizumab (%)
|
Density of bound samalizumab (MFI)
|
|---|
|
Pre-dose
|
Day 1
|
Pre-dose
|
Day 1
|
|---|
|
50 mg/m2 (n = 4)
|
0.3–0.7
|
1.1–3.3
|
1.9–3.1
|
3.3–4.1
|
|
100 mg/m2 (n = 5)
|
0.2–2.4
|
0.2–9.5
|
3.5–5.6
|
5.0–11.1
|
|
200 mg/m2 (n = 2)
|
0.3–0.7
|
27.8–29.6
|
3.2–3.3
|
16.6–19.3
|
|
300 mg/m2 (n = 2)
|
0.5–0.7
|
5–28.6
|
1.7–3.0
|
5.6–16.8
|
|
400 mg/m2 (n = 3)
|
1.1–5.7
|
1.7–71.3
|
1.7–3.4
|
4.6–26.6
|
|
500 mg/m2 (n = 5)
|
0.5–2.1
|
1–47.0
|
1–3.7
|
1.9–17.6
|
- Binding of samalizumab to CD200 on circulating CLL cells was evaluated by multi-parametric flow cytometry using a fluorescently-labeled monoclonal antibody specific for samalizumab (7B8) together with a second anti-CD200 antibody (IB2) specific for an epitope of CD200 distinct from the binding site of samalizumab
